E6011 + Placebo

Phase 1Withdrawn

0 views this week 0 watching💤 Quiet

Interest: 21/100

Hype Score

Development Stage

✓

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Crohn's Disease

Conditions

Crohn's Disease

Trial Timeline

Dec 1, 2014 → Apr 1, 2016

NCT ID

NCT02249078

About E6011 + Placebo

E6011 + Placebo is a phase 1 stage product being developed by Eisai for Crohn's Disease. The current trial status is withdrawn. This product is registered under clinical trial identifier NCT02249078. Target conditions include Crohn's Disease.

What happened to similar drugs?

9 of 20 similar drugs in Crohn's Disease were approved

Approved (9) Terminated (4) Active (11)

✅adalimumabAbbVieApproved

✅Infliximab 5 mg/kg + Infliximab 5 mg/kg every 6 weeks + Infliximab 7 mg/kg every 8 weeksMerckApproved

✅Infliximab + Prednisolone + AzathioprinePfizerApproved

✅Celebrex + placeboPfizerApproved

✅Cimzia + MesalamineUCBApproved

✅Certolizumab PegolUCBApproved

✅certolizumab pegol + certolizumab pegol + certolizumab pegol + certolizumab pegolUCBApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (6)

NCT ID	Phase	Status	Start	Completion	Indication
NCT03733314	Phase 2	Completed	Apr 25, 2019	Apr 3, 2024	Crohn's Disease
NCT03092765	Phase 2	Terminated	May 29, 2017	Oct 22, 2018	Primary Biliary Cholangitis
NCT02960490	Phase 2	Completed	Nov 26, 2016	Nov 25, 2019	Rheumatoid Arthritis
NCT02960438	Phase 2	Completed	Oct 20, 2016	Sep 17, 2019	Rheumatoid Arthritis
NCT02249078	Phase 1	Withdrawn	Dec 1, 2014	Apr 1, 2016	Crohn's Disease
NCT02146261	Phase 1	Completed	Sep 1, 2013	Apr 1, 2014	Healthy

Competing Products

20 competing products in Crohn's Disease

See all competitors

Product	Company	Stage	Hype Score
CT-P13 + Remicade	Celltrion	Phase 3	40
CT-P13 + CT-P13 + CT-P13 + CT-P13 + CT-P13 + CT-P13	Celltrion	Phase 1	29
CT-P13 SC (Infliximab)	Celltrion	Phase 3	40
CP-461	Astellas Pharma	Phase 2	35
E6011 2 mg/kg + E6011 5 mg/kg + E6011 10 mg/kg + E6011 15 mg/kg	Eisai	Phase 1/2	32
E6011 + Placebo	Eisai	Phase 2	35
adalimumab + adalimumab + placebo	Eisai	Phase 2/3	38
adalimumab	Eisai	Phase 2/3	38
Mirikizumab + Mirikizumab + Ustekinumab + Ustekinumab + Placebo + Placebo	Eli Lilly	Phase 3	40
Mirikizumab	Eli Lilly	Phase 3	47
Mirikizumab + Mirikizumab + Tirzepatide + Placebo	Eli Lilly	Phase 3	47
Mirikizumab + Placebo	Eli Lilly	Phase 2	35
Mirikizumab	Eli Lilly	Phase 3	44
Matching Placebo for Upadacitinib + Upadacitinib	AbbVie	Phase 3	40
Adalimumab + Placebo	AbbVie	Phase 3	40
Upadacitinib + Placebo for Upadacitinib	AbbVie	Phase 3	40
Placebo + ABT-494	AbbVie	Phase 2	35
ABT-494	AbbVie	Phase 2	35
Risankizumab + Comparator	AbbVie	Pre-clinical	33
placebo for risankizumab + risankizumab IV + risankizumab SC	AbbVie	Phase 3	40